MedPath

Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients

Phase 3
Terminated
Conditions
Crohn's Disease
Interventions
Drug: placebo
Registration Number
NCT01986127
Lead Sponsor
Sara Varea
Brief Summary

We study if the administration of intralesional Adalimumab (directly injected in the stricture) associated to endoscopic dilatation has a higher success rate at week 8 compared with placebo in patients with Crohn's disease who had confirmed intestinal stenosis (3 stenosis as maximum)

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
26
Inclusion Criteria
  • Patients of both sexes older than 18 years
  • Patient diagnosed of CROHN´s disease
  • Patient with intestinal stenosis length equal or less than 5cm previously confirmed with bowel magnetic resonance imaging (3 stenosis as maximum)
  • Stenosis no permeable for endoscopy(12mm in case of accessible stenosis with conventional colonoscopy and 10mm in case of accessible stenosis with balloon enteroscopy)
  • Dilated stenosis according to endoscopist criteria (pass or no the endoscopy)
  • Patient capable of participate in the examinations required by the study
  • Patient after being informed, give his/her informed consent in writing
Exclusion Criteria
  • Patients with large intestinal stenosis (more than 6cm) and multiples
  • Patients with previous or actual treatment with anti-tumor necrosis factor (anti-TNF) drugs
  • Patients with positive serology to hepatitis B virus(HBV),hepatitis C virus (HCV), or HIV
  • Patients with positive screening to Tuberculosis(positive PPD)
  • Established contraindication to anti-TNF drugs
  • Existence of fistulous tracts associated with intestinal stenosis
  • Neoplastic process associated with stenosis or in another location
  • Pregnancy or breastfeeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
salineplacebo5 ml of saline
AdalimumabAdalimumabsingle administration of Adalimumab 80mg diluted in 5ml saline
Primary Outcome Measures
NameTimeMethod
Success of endoscopic dilatationat week 8

Successful dilatation means the passage of the endoscope (or enteroscopy colonoscope) through the stenosis

Secondary Outcome Measures
NameTimeMethod
success of endoscopic dilatationat week 52

The success of endoscopic dilatation at week 52 means absence of clinical subocclusion, no necessity of surgical nor endoscopic dilatation

Mucosal healingat week 8

* Anastomotic strictures: We define mucosal healing as a Rutgeerts \< or equal 2 with at least 1 point of improvement (añadir el score)

* Primary strictures: Absence of ulcers after treatment

proportion of patients that develop anti-adalimumab antibodiesat the end of the study
Stenosis measurebaseline

The endoscopic stenosis diameter will be estimated pre and post-dilatation

Histological cureat week 8

We consider histological cure if:

* Epithelial damage is \< or equal 1

* Architectural changes is \< or equal 1

* Infiltration of mononuclear cells in lamina propria is \< or equal 1

* Polymorphonuclear cells in the lamina propria = 0

* Polymorphonuclear cells in epithelium = 0

* Absence of erosions and ulcers (based ib scoring system for Histologic Abnormalities in Crohn's disease Mucosal Biopsy Specimens - Title: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum Author(s): D'Haens, Geert R.; Geboes, Karel; Peeters, Mark; et al. Source: Gastroenterology Volume: 114 Issue: 2 Pages: 262-267 Published: Feb., 1998)

adverse eventsat the end of the study

Trial Locations

Locations (13)

Hospital Moises Broggi

🇪🇸

Sant Joan Despí, Barcelona, Spain

Complexo Hospitalario Arquitecto Marcide -Novoa Santos

🇪🇸

Ferrol, A Coruña, Spain

Complexo Hospitalario Universitario de Santiago

🇪🇸

Santiago de Compostela, A Coruña, Spain

Hospital Mutua de Terrassa

🇪🇸

Terrassa, Barcelona, Spain

Hospital Universitario Puerta del Hierro

🇪🇸

Majadahonda, Madrid, Spain

Hospital Universitari Son Espases

🇪🇸

Palma de Mallorca, Mallorca, Spain

Hospital General Universitario de Alicante

🇪🇸

Alicante, Spain

Hospital Clinic of Barcelona

🇪🇸

Barcelona, Spain

Hospital del Mar

🇪🇸

Barcelona, Spain

Hospital Josep Trueta

🇪🇸

Girona, Spain

Complejo asistencial universitario de Burgos

🇪🇸

Burgos, Spain

Hospital La Fe

🇪🇸

Valencia, Spain

Hospital La Paz

🇪🇸

Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath